Χώρα: Ελβετία
Γλώσσα: Ιταλικά
Πηγή: Swissmedic (Swiss Agency for Therapeutic Products)
haemagglutininum influenzae A (H1N1) (Virus Stamm A/Guangdong-Maonan/SWL1536/2019 (H1N1)-like: reassortant virus CNIC-1909 derived from A/Guangdong-Maonan/SWL1536/2019), haemagglutininum influenzae A (H3N2) (Virus Stamm A/Hong Kong/2671/2019 (H3N2)-like: reassortant virus NIB-121 derived from A/Hong Kong/2671/2019), haemagglutininum influenzae B (Virus Stamm B/Washington/02/2019-like: reassortant virus B/Washington/02/2019 (Victoria lineage))
GlaxoSmithKline AG
J07BB02
haemagglutininum influenzae A (H1N1) (Virus Stamm A/Guangdong-Maonan/SWL1536/2019 (H1N1)-like: reassortant virus CNIC-1909 derived from A/Guangdong-Maonan/SWL1536/2019), haemagglutininum influenzae A (H3N2) (Virus Stamm A/Hong Kong/2671/2019 (H3N2)-like: reassortant virus NIB-121 derived from A/Hong Kong/2671/2019), haemagglutininum influenzae B (Virus Stamm B/Washington/02/2019-like: reassortant virus B/Washington/02/2019 (Victoria lineage))
Sospensione iniettabile
haemagglutininum influenzae A (H1N1) (Virus Stamm A/Guangdong-Maonan/SWL1536/2019 (H1N1)-like: reassortant virus CNIC-1909 derived from A/Guangdong-Maonan/SWL1536/2019) 15 µg, haemagglutininum influenzae A (H3N2) (Virus Stamm A/Hong Kong/2671/2019 (H3N2)-like: reassortant virus NIB-121 derived from A/Hong Kong/2671/2019) 15 µg, haemagglutininum influenzae B (Virus Stamm B/Washington/02/2019-like: reassortant virus B/Washington/02/2019 (Victoria lineage)) 15 µg, haemagglutininum influenzae B (Virus Stamm B/Phuket/3073/2013 (Yamagata lineage)) 15 µg, polysorbatum 80, octoxinolum-10, natrii chloridum, magnesii chloridum hexahydricum, dinatrii phosphas dodecahydricus, kalii dihydrogenophosphas, kalii chloridum, alpha-tocopheroli hydrogenosuccinas, aqua ad iniectabilia q.s. ad suspensionem pro 0.5 ml, residui: ovalbuminum, formaldehydum, natrii desoxycholas, gentamicini sulfas, hydrocortisonum.
B
Vaccini
Immunizzazione attiva contro l'Influenza, a partire da 36 Mesi
2014-05-28